Syndax Pharmaceuticals, Inc. (SNDX) Operating income 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) annual operating income history from SEC filings — each fiscal year as reported.
-$273.1MFY2025 · since FY2016: -$43.8M → -$273.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$273.1M | +19.6% |
| FY2024 | -$339.7M | -47.7% |
| FY2023 | -$230.0M | -51.5% |
| FY2022 | -$151.8M | -678.8% |
| FY2021 | $26.2M | +136.7% |
| FY2020 | -$71.4M | -24.1% |
| FY2019 | -$57.5M | +24.2% |
| FY2018 | -$75.9M | -22.5% |
| FY2017 | -$62.0M | -41.6% |
| FY2016 | -$43.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SNDX financial trends
SNDX RevenueSNDX Net incomeSNDX Net marginSNDX Gross profitSNDX Gross marginSNDX Operating marginSNDX Operating cash flowSNDX Free cash flowSNDX Capital expendituresSNDX Return on equitySNDX Stock buybacksSNDX Dividends paidSNDX Total assetsSNDX Total liabilitiesSNDX Shareholders’ equitySNDX overview →